A novel prognostic system based on clinical and laboratory parameters for childhood Guillain-Barre syndrome
- PMID: 35753018
- DOI: 10.1007/s13760-022-01960-x
A novel prognostic system based on clinical and laboratory parameters for childhood Guillain-Barre syndrome
Abstract
Aim: To develop a score based on clinical and laboratory parameters in acute-phase of GBS to predict outcome at 6 months.
Methods: Clinical and laboratory assessment at admission including blood neutrophil-to-lymphocyte ratio (NLR), pre and post-immunotherapy serum albumin was prospectively performed in pediatric-GBS cases at a tertiary-care hospital over 1 year. Clinical features and laboratory test results were compared between children with complete (Hughes Disability Score; HDS ≤ 1) and incomplete recovery (HDS > 1) at 6 months from onset, using univariate and multivariate analysis. Area-under-receiver-operating-characteristic-curve (AUC) of predictors of prognosis and their optimal cutoffs were assessed.
Results: Forty-six patients were enrolled (mean age 69.1 ± 35.2 months; male 57.6%). Factors on admission that independently predicted poor-outcome at 6 months were older age, feeble voice, lower NLR and lower post-immunotherapy serum albumin. AUCs and optimal cutoffs of NLR and post-immunotherapy serum albumin for predicting disability at 6 months were 0.729, 0.781 and ≤ 1.65, ≤ 34.5 g/L, respectively. AUCs of clinical parameters such as older age and feeble voice were 0.749 and 0.713 respectively. King GBS outcomescore including all predictors had maximum AUC of 0.971 (95% CI 0.921-1.02). The score at cutoff ≥ 3 demonstrated excellent sensitivity (92.3%) and specificity (96.7%) to determine poor outcome.
Conclusions: This new prognostic system may be beneficial in recognising children-at-risk of poor prognosis who may benefit from additional treatment.
Keywords: Children; Guillain–Barre syndrome; Hughes disability score; Neutrophil–lymphocyte ratio; Prognosis; Serum albumin; Voice.
© 2022. The Author(s) under exclusive licence to Belgian Neurological Society.
Similar articles
-
Early predictors of functional disability in Guillain-Barré Syndrome.Acta Neurol Belg. 2019 Dec;119(4):555-559. doi: 10.1007/s13760-019-01133-3. Epub 2019 Apr 8. Acta Neurol Belg. 2019. PMID: 30963477
-
The clinical significance of systemic immune-inflammation index and platelet/neutrophil to lymphocyte ratio in Guillain-Barré syndrome.Clin Neurol Neurosurg. 2023 Dec;235:108015. doi: 10.1016/j.clineuro.2023.108015. Epub 2023 Oct 17. Clin Neurol Neurosurg. 2023. PMID: 37898029
-
Neutrophil-lymphocyte ratio in Guillain-Barré syndrome: A prognostic biomarker of severe disease and mechanical ventilation in Bangladesh.J Peripher Nerv Syst. 2023 Mar;28(1):47-57. doi: 10.1111/jns.12531. Epub 2023 Feb 8. J Peripher Nerv Syst. 2023. PMID: 36700342 Free PMC article.
-
[The prognosis and prognostic factor of Guillain-Barré Syndrome].Rinsho Shinkeigaku. 2020 Apr 24;60(4):247-252. doi: 10.5692/clinicalneurol.cn-001398. Epub 2020 Mar 31. Rinsho Shinkeigaku. 2020. PMID: 32238748 Review. Japanese.
-
Serum C3 complement levels predict prognosis and monitor disease activity in Guillain-Barré syndrome.J Neurol Sci. 2023 Jan 15;444:120512. doi: 10.1016/j.jns.2022.120512. Epub 2022 Nov 28. J Neurol Sci. 2023. PMID: 36462224 Review.
Cited by
-
Diagnostic Pitfalls in Guillain-Barré Syndrome: Case Report and Literature Review.Children (Basel). 2022 Dec 15;9(12):1969. doi: 10.3390/children9121969. Children (Basel). 2022. PMID: 36553412 Free PMC article. Review.
References
-
- Robert KY, Usuki S, Ariga T (2006) Ganglioside molecular mimicry and its pathological roles in Guillain-Barre syndrome and related diseases. Infect Immun 74:6517–6527 - DOI
-
- Stoian A, Moțățăianu A, Bărcuțean L et al (2020) Understandig the mechanism of action of intravenous immunoglobulins: a ten years experience in treating guillain-barré syndrome. Farmacia 68:426–435 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical